🟢 SeaStar Medical is trading 10.5% up in pre-market after FDA confirms QUELIMMUNE post-approval study completion

SeaStar Medical is trading at $2.42 (+10.51%) after the FDA confirmed fulfillment of QUELIMMUNE’s required post-approval study.

• On November 3, 2026, hospitals could use the therapy without the registry’s research infrastructure.
• This may widen access for eligible pediatric patients. No pre-market volume or activity details were provided.